Anika Therapeutics (ANIK) Capital Expenditures (QoQ) (2010 - 2026)
Anika Therapeutics (ANIK) Capital Expenditures (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Anika Therapeutics | 282.86 Mn | 244.45 Mn | 21.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.26% |
| Mar 31, 2026 | 120.83% |
| Dec 31, 2025 | -65.66% |
| Sep 30, 2025 | 28.63% |
| Jun 30, 2025 | -48.05% |
| Mar 31, 2025 | 116.07% |
| Dec 31, 2024 | 7.48% |
| Sep 30, 2024 | -64.27% |
| Jun 30, 2024 | 88.22% |
| Mar 31, 2024 | -1.74% |
| Dec 31, 2023 | 148.31% |
| Sep 30, 2023 | -49.14% |
| Jun 30, 2023 | 4.90% |
| Mar 31, 2023 | -45.08% |
| Dec 31, 2022 | 49.56% |
| Sep 30, 2022 | -12.84% |
| Jun 30, 2022 | 46.30% |
| Mar 31, 2022 | 17.66% |
| Dec 31, 2021 | -12.23% |
| Sep 30, 2021 | -40.61% |